Aggressive Systemic Mastocytosis (ASM)
An advanced form of systemic mastocytosis in which mast cell infiltration causes measurable organ damage, requiring active cytoreductive treatment.
- Organ damage (C-findings) present
- Driven by KIT D816V mutation
- Targeted therapy can improve outcomes
- Requires specialist hematology care
- Most Common In
- Adults (often older adults)
- Key Mutation
- KIT D816V (majority of cases)
- Defining Feature
- Organ damage (C-findings)
- Disease Course
- More aggressive than ISM/SSM
- Advanced Therapies
- KIT inhibitors, stem cell transplant
Condition Overview
Aggressive systemic mastocytosis (ASM) is an advanced subtype of systemic mastocytosis defined by the presence of organ damage, known as C-findings, resulting from extensive mast cell infiltration of the bone marrow, liver, spleen, bone, or gastrointestinal tract. Unlike indolent or smoldering disease, ASM requires active treatment aimed at reducing mast cell burden and preserving organ function.
Types and Subtypes
ASM can occur on its own or together with another blood disorder, and rarely progresses to a leukemic form.
Symptoms and Signs
In addition to typical mast cell mediator symptoms, ASM often presents with signs of organ dysfunction from mast cell infiltration.
Causes and Risk Factors
ASM arises from the same underlying mast cell mutation biology as other systemic mastocytosis subtypes, typically representing disease progression or a higher initial mast cell burden.
Diagnosis and Investigations
Diagnosis of ASM requires confirming systemic mastocytosis criteria along with documenting at least one organ damage (C-finding) feature.
Staging and Risk Groups
ASM is defined by the presence of organ damage criteria (C-findings); risk groups further reflect the number and severity of organs affected and any associated hematologic neoplasm.
Standard Treatment
Treatment of ASM is aimed at reducing mast cell burden to restore or preserve organ function, generally requiring active systemic therapy.
Advanced & Emerging Therapies
Targeted KIT inhibitors have substantially changed treatment of ASM, and other novel approaches are under active investigation.
Targeted Therapy
Avapritinib
A KIT D816V-selective inhibitor approved for advanced systemic mastocytosis including ASM.
Targeted Therapy
Midostaurin
A multikinase inhibitor with activity against KIT D816V, used in advanced systemic mastocytosis.
Cellular Therapy
Allogeneic stem cell transplant
Considered for select patients with refractory ASM or ASM-AHN.
International Access
China-based clinical trial and specialist coordination
CancerFax can help connect patients with refractory ASM to international expert centers and trials.
Biomarkers & Precision Medicine
Molecular and laboratory markers in ASM help confirm organ damage, guide targeted therapy selection, and assess prognosis.
When to Seek a 2nd Opinion
Given the complexity of ASM, particularly when an associated hematologic neoplasm is present, specialist second opinions are strongly encouraged.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis in ASM is more guarded than in indolent or smoldering disease, though targeted therapies have meaningfully improved outcomes for many patients.
Supportive Care
Supportive care in ASM addresses the organ-specific complications of mast cell infiltration alongside general symptom management.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you access specialist review of your organ damage findings and explore targeted KIT-inhibitor and transplant options for ASM.
Get a free case reviewFrequently Asked Questions
ASM is an advanced form of systemic mastocytosis in which mast cell infiltration causes measurable damage to organs such as the liver, bone marrow, or bones.
Early signs can include unintentional weight loss, fatigue, abdominal swelling from liver or spleen enlargement, and bone pain.
ASM is defined by the presence of organ damage, while indolent and smoldering disease have no organ damage and are managed primarily with monitoring or symptom control.
Targeted KIT inhibitors such as avapritinib and midostaurin are standard first-line treatment, with stem cell transplant considered in select cases.
This is ASM occurring together with a second blood disorder, requiring combined treatment of both conditions.
Progression to mast cell leukemia is rare but represents the most aggressive form of the disease, requiring urgent treatment.
Allogeneic stem cell transplant may be considered for select patients with refractory ASM or ASM with associated hematologic neoplasm.
Organ damage is identified through blood counts, liver and kidney function tests, imaging, and bone assessments, referred to as C-findings.
Outlook varies based on organ involvement and treatment response; targeted therapies have improved outcomes for many patients, though prognosis should be discussed individually.
Yes. CancerFax can help you submit your medical reports for urgent specialist review, request a second opinion, explore targeted KIT-inhibitor or transplant options, and coordinate with international centers, including in China, if relevant to your case.
Get Urgent Support for Your ASM Diagnosis
Send your reports to CancerFax for specialist review and explore targeted therapy and transplant options without delay.